The U.S. Food and Drug Administration (FDA) has confirmed that the lowest dose of Novo Nordisk’s weight-loss medication, Wegovy, is available after nearly two years of scarcity. This announcement comes as all five dose strengths of Wegovy, along with all three doses of the diabetes therapy Ozempic, are now listed as available on the FDA’s shortage website.
Novo Nordisk attributes this success to a carefully managed U.S. supply strategy, aimed at meeting escalating demand for GLP-1 treatments like Wegovy and Ozempic, which support weight loss and blood sugar control. The company's gradual increase in shipments has enabled regular supplies to reach wholesalers.
In response to the growing demand, Novo Nordisk, along with Eli Lilly, has invested substantially to expand production capabilities. Both companies remain key players in the GLP-1 drug category, with Lilly’s Zepbound as the other prominent obesity treatment option currently available.
For more information, visit Reuters.
